Related references
Note: Only part of the references are listed.Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE
Maria Buti et al.
CLINICAL INFECTIOUS DISEASES (2016)
Hepatitis C Virus Gene Sequencing as a Tool for Precise Genotyping in the Era of New Direct Antiviral Agents
Francesca Ceccherini Silberstein et al.
HEPATOLOGY (2016)
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels
V. C. Di Maio et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions
Evguenia S. Svarovskaia et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Emergence of HCV resistance-associated variants in patients failing sofosbuvir-based regimens: an observational cohort
Elisabeth Andre-Garnier et al.
ANTIVIRAL THERAPY (2016)
From current status to optimization of HCV treatment: Recommendations from an expert panel
Antonio Craxi et al.
DIGESTIVE AND LIVER DISEASE (2016)
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir
Christoph Sarrazin et al.
GASTROENTEROLOGY (2016)
Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens
Jean-Michel Pawlotsky
GASTROENTEROLOGY (2016)
Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study
Paul Kwo et al.
HEPATOLOGY (2016)
Retreatment With Sofosbuvir and Simeprevir of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed a Daclatasvir-Containing Regimen
Christophe Hezode et al.
HEPATOLOGY (2016)
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)
Vincent Leroy et al.
HEPATOLOGY (2016)
Simeprevir Plus Sofosbuvir in Patients With Chronic Hepatitis C Virus Genotype 1 Infection and Cirrhosis: A Phase 3 Study (OPTIMIST-2)
Eric Lawitz et al.
HEPATOLOGY (2016)
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence
Fred Poordad et al.
HEPATOLOGY (2016)
RETREATMENT OF PATIENTS WHO FAILED DAA-COMBINATION THERAPIES: REAL-WORLD EXPERIENCE FROM A LARGE HEPATITIS C RESISTANCE DATABASE
J. Vermehren et al.
JOURNAL OF HEPATOLOGY (2016)
OMBITASVIR/PARITAPREVIR/R, DASABUVIR, AND SOFOSBUVIR TREATMENT OF PATIENTS WITH HCV GENOTYPE 1-INFECTION WHO FAILED A PRIOR COURSE OF DAA THERAPY: THE QUARTZ-I STUDY
F. Poordad et al.
JOURNAL OF HEPATOLOGY (2016)
SOFOSBUVIR/VELPATASVIR IN COMBINATION WITH RIBAVIRIN FOR 24 WEEKS IS EFFECTIVE RETREATMENT FOR PATIENTS WHO FAILED PRIOR NS5A CONTAINING DAA REGIMENS: RESULTS OF THE GS-US-342-1553 STUDY
E. J. Gane et al.
JOURNAL OF HEPATOLOGY (2016)
RETREATMENT OF HCV DAA FAILURES: HCV INFECTION MAY BE INCURABLE
C. Hezode et al.
JOURNAL OF HEPATOLOGY (2016)
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
Christoph Sarrazin
JOURNAL OF HEPATOLOGY (2016)
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection A Randomized Trial
Stefan Zeuzem et al.
ANNALS OF INTERNAL MEDICINE (2015)
Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir
Preethi Krishnan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Hepatitis C virus drug resistance-associated substitutions: State of the art summary
Erik Lontok et al.
HEPATOLOGY (2015)
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
Raymond T. Chung et al.
HEPATOLOGY (2015)
RESISTANCE ANALYSIS OF VIROLOGIC FAILURES IN HEPATITIS C GENOTYPE 1 INFECTED PATIENTS TREATED WITH GRAZOPREVIR/ELBASVIR plus /- RIBAVIRIN: THE C-WORTHY STUDY
S. Black et al.
JOURNAL OF HEPATOLOGY (2015)
Management of direct-acting antiviral agent failures
Maria Buti et al.
JOURNAL OF HEPATOLOGY (2015)
PREVALENCE OF PRE-TREATMENT NS5A AND NS5B RESISTANCE ASSOCIATED VARIANTS AND GENETIC VARIATION WITHIN HCV SUBTYPES ACROSS DIFFERENT COUNTRIES
E. Svarovskaia et al.
JOURNAL OF HEPATOLOGY (2015)
LONG-TERM PERSISTENCE OF HCV NS5A VARIANTS AFTER TREATMENT WITH NS5A INHIBITOR LEDIPASVIR
H. Dvory-Sobol et al.
JOURNAL OF HEPATOLOGY (2015)
LONG-TERM FOLLOW-UP OF TREATMENT-EMERGENT RESISTANCE-ASSOCIATED VARIANTS IN NS3, NS5A AND NS5B WITH PARITAPREVIR/R-, OMBITASVIR- AND DASABUVIR-BASED REGIMENS
P. Krishnan et al.
JOURNAL OF HEPATOLOGY (2015)
RETREATMENT OF PATIENTS WHO FAILED 8 OR 12 WEEKS OF LEDIPASVIR/SOFOSBUVIR- BASED REGIMENS WITH LEDIPASVIR/SOFOSBUVIR FOR 24 WEEKS
E. Lawitz et al.
JOURNAL OF HEPATOLOGY (2015)
EASL Recommendations on Treatment of Hepatitis C 2015
JOURNAL OF HEPATOLOGY (2015)
Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy
Satoshi Yoshimi et al.
JOURNAL OF MEDICAL VIROLOGY (2015)
Clinical Evidence and Bioinformatics Characterization of Potential Hepatitis C Virus Resistance Pathways for Sofosbuvir
Eric F. Donaldson et al.
HEPATOLOGY (2015)
Infrequent Development of Resistance in Genotype 1-6 Hepatitis C Virus-Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
Evguenia S. Svarovskaia et al.
CLINICAL INFECTIOUS DISEASES (2014)
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
Eric Lawitz et al.
LANCET (2014)
Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment
Doug J. Bartels et al.
JOURNAL OF VIROLOGY (2013)
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies
Richard J. O. Barnard et al.
VIROLOGY (2013)
Hepatitis C Viral Evolution in Genotype 1 Treatment-Naive and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials
Tara L. Kieffer et al.
PLOS ONE (2012)
Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
Christoph Sarrazin et al.
GASTROENTEROLOGY (2010)
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
Libin Rong et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Share Paper
